Clarkston Capital Partners LLC trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 85.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 198,340 shares of the company’s stock after selling 1,133,313 shares during the quarter. Clarkston Capital Partners LLC’s holdings in Kenvue were worth $3,421,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in the business. Storgate LLC bought a new stake in Kenvue during the 4th quarter worth approximately $314,000. Gator Capital Management LLC bought a new stake in Kenvue during the 4th quarter worth approximately $1,355,000. Quadrant Capital Group LLC grew its holdings in Kenvue by 189.4% during the 4th quarter. Quadrant Capital Group LLC now owns 64,296 shares of the company’s stock worth $1,109,000 after acquiring an additional 42,077 shares during the last quarter. Northwest & Ethical Investments L.P. grew its holdings in Kenvue by 23.2% during the 4th quarter. Northwest & Ethical Investments L.P. now owns 187,853 shares of the company’s stock worth $3,240,000 after acquiring an additional 35,327 shares during the last quarter. Finally, Federation des caisses Desjardins du Quebec grew its holdings in Kenvue by 20.0% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 490,442 shares of the company’s stock worth $8,461,000 after acquiring an additional 81,700 shares during the last quarter. 97.64% of the stock is owned by institutional investors.
Kenvue Stock Up 0.3%
Shares of NYSE KVUE opened at $18.13 on Friday. The company has a market capitalization of $34.80 billion, a P/E ratio of 21.32, a price-to-earnings-growth ratio of 1.37 and a beta of 0.54. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $22.87. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The company’s 50 day moving average price is $17.43 and its 200-day moving average price is $17.53.
Kenvue Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date was Wednesday, May 13th. Kenvue’s payout ratio is presently 97.65%.
Insider Activity
In related news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.59% of the stock is owned by insiders.
Analysts Set New Price Targets
A number of research firms have weighed in on KVUE. UBS Group reduced their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, April 7th. Zacks Research raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Citigroup reduced their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. Canaccord Genuity Group boosted their price target on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research report on Wednesday, February 18th. Finally, Weiss Ratings downgraded shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $19.33.
Get Our Latest Research Report on KVUE
About Kenvue
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Stories
- Five stocks we like better than Kenvue
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
